Log inStart free trialBook a demo
Log inStart free trial
Media Database
>
Beth Snyder Bulik

Beth Snyder Bulik

Senior Editor at ENDPOINTS NEWS

Contact this person
Email address
b*****@*******.comGet email address
Influence score
44
Location
United States
Languages
  • English
Covering topics
  • Marketing
  • Health & Medicine

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

endpts.com

Cannes Lions taps Edelman, Dentsu execs to lead the pharma ... - Endpoints News

The Cannes Li­ons fes­ti­val and award show an­nounced that Dentsu Health’s Col­lette Douai­hy will lead the phar­ma ju­ry and Edel­man’s Wendy Chan will head up health and well­ness. Both have pre­vi­ous­ly been Cannes judges in health cat­e­gories. Chan, who is the health cre­ative lead for Asia Pa­cif­ic at Edel­man, was on the phar­ma ju­ry last year, and Douai­hy, who is glob­al chief cre­ative of­fi­cer at Dentsu Health, served on the phar­ma ju­ry in 2022 and on health and well­ness in 20…
almost 2 years ago
endpts.com

EMD Serono lays out MS therapies' immune-system suppression ... - E...

EMD Serono is lean­ing on drug dif­fer­en­ti­a­tion in a new dig­i­tal and so­cial me­dia cam­paign for Maven­clad, its mul­ti­ple scle­ro­sis treat­ment. The “B Cells and RMS” cam­paign de­scribes the B cell and po­ten­tial long-term im­mune sys­tem sup­pres­sion that can oc­cur in MS pa­tients tak­ing high-ef­fi­ca­cy ther­a­pies (HET), in­clud­ing mon­o­clon­al an­ti­bod­ies like Roche’s Ocre­vus and Bio­gen’s Tysabri, and S1P mod­u­la­tors like No­var­tis’ Kes­imp­ta. Maven­clad is al­so an…
almost 2 years ago
endpts.com

Novo Nordisk restarts advertising for obesity drug Wegovy with new ...

No­vo Nordisk is restart­ing its We­govy ad­ver­tis­ing with a new in­tro­spec­tive cam­paign en­cour­ag­ing peo­ple to “Be­lieve On” af­ter an eight-month pause on its cam­paign re­lat­ed to the weight man­age­ment ther­a­py. With We­govy short­ages still an is­sue, the new “brand eq­ui­ty” ad­ver­tis­ing aims for brand-build­ing and emo­tion­al con­nec­tions, show­ing the re­al­is­tic ups and downs of obe­si­ty and chron­ic weight man­age­ment in the new­ly launched TV com­mer­cial. The We­gov…
almost 2 years ago
endpts.com

Evaluate buys forecasting group to build out prediction software an...

Eval­u­ate is boost­ing its fore­cast­ing prac­tice with the ac­qui­si­tion of J+D Fore­cast­ing and its phar­ma in­dus­try soft­ware so­lu­tions. Eval­u­ate, known for its con­sen­sus da­ta and fore­cast­ing, has worked with J+D over the past few years on projects, sup­ply­ing da­ta for J+D soft­ware mod­el­ing, and found the two were a good fit, Eval­u­ate chief rev­enue of­fi­cer Chris Kel­ley said. “We have the da­ta that cus­tomers sub­scribe to and al­so con­sult­ing strat­e­gy to help the…
almost 2 years ago
endpts.com

Want to make better pharma ads? Try using humor and more ... - Endp...

Phar­ma ad­ver­tis­ing hits the mark for news and rel­e­vance, but typ­i­cal­ly dis­ap­points when it comes to be­ing en­joy­able. That’s ac­cord­ing to Kan­tar an­a­lyst Pol­ly Wyn Jones who re­cent­ly did a deep dive re­port on the cat­e­go­ry af­ter it moved up to be­come now the sec­ond-largest ad spend­ing cat­e­go­ry. Phar­ma jumped ahead of tech brands, and al­though it still spends less than con­sumer pack­aged goods, the cat­e­go­ry spent an all-time high of $18 bil­lion on ad­ver­tis­i…
almost 2 years ago
endpts.com

Lupus drug market growing as physicians adopt newer options ... - E...

With three rel­a­tive­ly new drugs, plus a busy pipeline in both sys­temic lu­pus ery­the­mato­sus (SLE) and lu­pus nephri­tis (LN), the lu­pus mar­ket has been tak­ing off. The LN are­na is es­pe­cial­ly busy now with two com­peti­tors gain­ing steam, but SLE is al­so on physi­cians’ minds with the po­ten­tial for CAR-T cell ther­a­py treat­ment on the hori­zon, ac­cord­ing to re­search from Spher­ix Glob­al In­sights. While lu­pus CAR-T stud­ies have been around for a few years, the po­ten­tia…
almost 2 years ago
endpts.com

Physicians are on board with mRNA vaccines, but worry about ... - E...

Physi­cians to­day are gen­er­al­ly pos­i­tive about mR­NA vac­cines, but many are con­cerned about the mis­in­for­ma­tion they hear from pa­tients. Al­most two-thirds (65%) of health­care pro­fes­sion­als point­ed to mis­in­for­ma­tion and con­spir­a­cy the­o­ries as “ma­jor hur­dles” in mR­NA vac­cine adop­tion, ac­cord­ing to a re­cent Zoom­Rx sur­vey. “The chal­lenges we found were around mis­in­for­ma­tion and mis­trust,” said Con­rad Wal­gren, se­nior di­rec­tor, mar­ket­ing at Zoom­Rx. “…
almost 2 years ago
endpts.com

GSK's ViiV sponsors new season of RuPaul TV show to spark HIV ... -...

GSK’s Vi­iV Health­care is get­ting in­to a new kind of race on Fri­day — “Ru­Paul’s Drag Race” re­al­i­ty show on MTV — as the spon­sor of sea­son 16. The HIV-fo­cused phar­ma is lever­ag­ing its new part­ner­ship with the “cul­tur­al phe­nom­e­non” show to gen­er­ate con­ver­sa­tions about HIV pre­ven­tion, a GSK spokesper­son said in an email. Vi­iV’s drug Apre­tude (cabote­gravir) is the first long-act­ing in­jectable for HIV PrEP ap­proved in late 2021. Two oth­er FDA-ap­proved PrEP op­tion…
almost 2 years ago
endpts.com

Klick Health nabs award-winning creative director Tim Jones to lead...

Tim Jones is mov­ing to Klick Health. The vet­er­an phar­ma and health agency cre­ative chief and award win­ner joined the in­de­pen­dent agency this week as its ex­ec­u­tive cre­ative di­rec­tor based in Lon­don. He will lead Klick’s EMEA cre­ative team and glob­al ex­pan­sion. Jones has led cre­ative teams at pow­er­house health and phar­ma agen­cies, most re­cent­ly as chief cre­ative of­fi­cer, phar­ma, at Grey Group. Be­fore that he was ex­ec­u­tive cre­ative di­rec­tor at Mc­Cann Health Ne…
almost 2 years ago
endpts.com

Brand drug naming faces challenges in emerging categories, expert ....

As brand drug nam­ing gets more dif­fi­cult, some ther­a­py ar­eas like obe­si­ty and Alzheimer’s dis­ease are fac­ing even more chal­lenges. That’s be­cause both are tra­di­tion­al­ly more con­ser­v­a­tive cat­e­gories when it comes to the kinds of names the FDA will al­low. Hint­ing at ben­e­fits, or even sub­tle im­pli­ca­tions, such as weight loss or mem­o­ry gain, are par­tic­u­lar­ly frowned up­on, said Brand In­sti­tute’s pres­i­dent of cre­ative, Scott Pier­grossi.
almost 2 years ago
endpts.com

MarketingRx roundup: Gilead, Pfizer sponsor divas' benefit concert ...

Gilead Sci­ences and Pfiz­er are tap­ping in­to their in­ner di­vas with spon­sor­ships of an an­nu­al celebri­ty-packed ben­e­fit con­cert and fundrais­er for HIV/AIDS and oth­er health pro­grams. The 33rd an­nu­al “DI­VAS Sim­ply Singing” de­buted live (for the first time since 2019) in De­cem­ber and is now avail­able for stream­ing, fea­tur­ing host Sh­eryl Lee Ralph and per­form­ers Jordin Sparks, Lav­erne Cox, Tina Knowles and Jen­nifer Hud­son.
almost 2 years ago